Is Hexo Corp (TSX:HEXO) a Buy After Earnings?

Hexo Corp’s (TSX:HEXO) latest financial results were a bit of a flop. Is this an opportunity for investors?

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Much of the investing world holds its breath whenever one of the top marijuana companies reports its quarterly earnings. Given that we’re still in the early stages of the development of the industry, it’s critical to pay attention to how the market develops and which companies are making a major impact. The latest major pot company to report its quarterly earnings was Hexo Corp (TSX:HEXO). Let’s see how the Quebec-based company did.

Hexo misses on net revenue expectations

Hexo’s gross cannabis revenue was up a whopping 1,285% year over year. This much isn’t particularly surprising; marijuana companies have been racking up sales recently, especially since recreational uses were legalized. However, Hexo’s net revenue, which was about $13 million, declined by about 3% quarter over quarter, falling short of analyst expectations by about $2 million.

Naturally, this didn’t bode well for investors. The firm’s stock fell sharply (by as much as 8%) on the day its earnings were released. Note that Hexo actually beat on earnings estimates, reporting a net loss of $0.04 per share as opposed to the consensus estimates of $0.05 per share.

Increasing production capacity

Hexo is projected to become one of the dozen (or so) cannabis companies in Canada with a production capacity above 100,000 kilograms per year at its peak. The firm will be able to produce in excess of 150,000 kilograms per year. During its latest reported quarter, Hexo produced 9,804 kilograms of dried cannabis, an increase of 98% over the previous quarter.

Further, the firm sold 2,904 kilograms of cannabis, an 8% increase from the previous quarter. Perhaps the most important news Hexo revealed was the closing of its acquisition of Newstrike Brands Ltd in late May. With this deal, Hexo gained access to about 1.8 million square feet of production space and 638,000 square feet of manufacturing and distribution space.

Plans to enter the U.S.

Hexo is finally making a play to enter the U.S market. While the company is still keeping some of the details close to its vest (investors weren’t told which eight U.S states the firm would do business in), Hexo did reveal that it plans on using its partnership with Molson Coors Brewing to start selling CBD derived products in the U.S. As a reminder, the U.S is the largest market in the world. Hexo’s decision to move its operations south of the border is great news for investors.

Strong guidance

Hexo is on track to double its revenues during the next quarter and record a net revenue of $400 million during fiscal year 2020. To do so, the firm will no doubt leverage its increased production capacity (especially now that the Newstrike acquisition is complete), and its numerous distribution channels. These include supply agreements with various Canadian provinces. In particular, the company’s five-year preferred supply agreement with the “Société des alcools du Québec” could generate in excess of $1 billion in revenues over the course of the agreement.

Should you buy?

I don’t believe that Hexo’s latest earnings report changes its fundamental investment thesis. Though the firm might have missed on net revenue estimates, it seems well positioned to take advantage of the upcoming legalization of cannabis-infused products via its partnership with Molson Coors Brewing. Also, the company is planning on entering the U.S market soon, which should raise its profile even more. Coupled with its already relatively strong domestic operations — which should be bolstered by its acquisition of Newstrike — Hexo still looks like an intriguing prospects.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny holds shares of Hexo Corp. The Motley Fool owns shares of Molson Coors Brewing.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »